R-CHOP is a chemotherapy regimen used primarily to treat aggressive non-Hodgkin lymphoma, consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Its clinical significance lies in its ability to improve survival rates and induce remission in patients with this malignancy. A key association is the risk of febrile neutropenia, a potentially serious complication that can arise due to bone marrow suppression from the treatment.
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.